You are about to leave DOPTELETHCP.com and go to an external page.
Please note that Sobi is not responsible for the content of the website you are about to visit.
CONTINUEGo back
For US healthcare professionals only
- Important Safety Information
- Prescribing Information
- Patient Information Leaflet
- For Patients
For US healthcare professionals only
DOPTELET CONNECTTM
Doptelet Connect is a free patient support program created by Sobi to provide individualized support to help eligible patients get access to Doptelet.
Doptelet Copay Program
The Doptelet Copay Program helps lower out-of-pocket costs for eligible patients receiving Doptelet. Eligible patients may pay as little as $0 per fill, up to a maximum $15,000 per calendar year.
See terms and conditions.
Outlines how the Doptelet Copay Program can help lower out-of-pocket costs for eligible patients receiving Doptelet
Patient Assistance Program Application
Assists patients who are underinsured or uninsured in determining their eligibility for financial assistance
View form en español
Validating insurance coverage, navigating the insurance process, and providing tools to help eligible patients get access to Doptelet.
Answering logistical questions and providing education and coordination around the specialty pharmacy fulfillment process.
Providing financial assistance options for eligible patients.
How Doptelet Connect Works
Prescription and Enrollment Form
Prescribes Doptelet and enrolls a patient into Doptelet Connect
View form en español
Describes the Doptelet Connect support offerings available to your patients and your office
Doptelet Connect Process Flow for Healthcare Professional (HCP) Offices
Explains relationship between the HCP offices and Doptelet Connect and the steps each may take during the access process
Authorization provides patient/caregiver access to the Doptelet Connect Patient Support Program
View form en español
Doptelet Access and Support Resource Guide
Offers a collection of digital resources for HCP office staff to navigate Doptelet access and reimbursement process.
DOWNLOADInside the guide you will find…
Enrollment Guide
Information to Help Complete the Prescription and Enrollment Form
Provides information on how to complete the Prescription and Enrollment Form
Gives an overview of the Doptelet access process and the pathway options from prescription through continuing care
Accessing Doptelet Documents
Doptelet Prior Authorization Resource Guide
Explains general steps in the PA process to help HCP offices get patients started on Doptelet
Accessing Doptelet: Specialty Pharmacies and Distributors
Lists the contact information for the specialty pharmacies and distributors that are authorized to dispense Doptelet
Provides useful codes to identify appropriate patients and assists with the billing and reimbursement of Doptelet
You’ve Been Prescribed Doptelet: Now What?
Outlines the process for patients in obtaining a Doptelet prescription with a Specialty Pharmacy
Have questions on access, support, and reimbursement?
Request to Speak to a Field Reimbursement Manager (FRM) and they will reach out to you soon.
Request a Field Reimbursement Manager
INDICATION
DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.
Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions.
DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts, and for signs and symptoms of thromboembolic events and institute treatment promptly.
Serious Adverse Reactions
Serious adverse reaction that occurred more frequently in patients treated with DOPTELET (9%; 12/128) compared to placebo (5%; 1/22) was headache, occurring in 1.6% (2/128).
Adverse Reactions
The most common adverse reactions (≥10%) in patients with chronic immune thrombocytopenia were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.
Postmarketing Experience
Following the approval of DOPTELET, hypersensitivity reactions involving the immune system, including, but not limited to, pruritus, rash, choking sensation, swollen face, and swollen tongue have been reported.
These are not all the possible risks associated with DOPTELET. Please see Full Prescribing Information for DOPTELET at www.doptelethcp.com
To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088.
For WAC pricing, visit doptelethcp.com/wac-pricing.
INDICATION
DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
